A comparative study to evaluate the safety and efficacy of Tablet Montelukast with Fexofenadine versus Tablet Montelukast with Levocetirizine in patient of Allergic Rhinitis in tertiary care centre.

Allergic rhinitis AR is a common chronic IgE mediated inflammatory condition of the nasal mucosa triggered by allergens presenting with symptoms such as sneezing nasal congestion rhinorrhea and nasal itching Combination therapy with leukotriene receptor antagonists and antihistamines is widely used to achieve better symptom control This study aims to compare the safety and efficacy of two such combinations Montelukast with Fexofenadine versus Montelukast with Levocetirizine in patients diagnosed with allergic rhinitis attending a tertiary care centre This prospective randomized open label study will involve 277 patients aged 18 to 65 years divided equally into two groups Group A will receive Montelukast 10 mg with Fexofenadine 120 mg once daily while Group B will receive Montelukast 10 mg with Levocetirizine 5 mg once daily The follow up will be done at 15 days one month and two months Efficacy will be assessed using the Total Nasal Symptom Score TNSS and quality of life questionnaires Safety will be evaluated based on reported adverse effects particularly sedation and any laboratory parameters if required It is anticipated that both combinations will offer significant symptomatic relief Montelukast Fexofenadine may show better tolerability with fewer sedative effects whereas Montelukast Levocetirizine may provide slightly superior symptom control with more sedation The findings may help clinicians choose the most appropriate and patient friendly option for allergic rhinitis Ethical approval and informed consent will be ensured throughout the study